Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response

Open access
Lopez‐Girona, Antonia, Heintel, Daniel, Zhang, Ling‐Hua, Mendy, Derek, Gaidarova, Svetlana, Brady, Helen, Bartlett, Justin Blake, Schafer, Peter H., Schreder, Martin, Bolomsky, Arnold, Hilgarth, Bernadette, Zojer, Niklas, Gisslinger, Heinz, Ludwig, Heinz, Daniel, Tom, Jäger, Ulrich, Chopra, Rajesh·2011·British Journal of Haematology

Abstract

Summary: Overexpression of the transcription factor interferon regulatory factor‐4 (IRF4), which is common in multiple myeloma (MM), is associated with poor prognosis. Patients with higher IRF4 expression have significantly poorer overall survival than those with low IRF4 expression. Lenalidomide is an IMiD® immunomodulatory compound that has both tumouricidal and immunomodulatory activity in MM. This study showed that lenalidomide downregulated IRF4 levels in MM cell lines and bone marrow samples within 8 h of drug exposure. This was associated with a decrease in MYC levels, as well as an initial G1 cell cycle arrest, decreased cell proliferation, and cell death by day 5 of treatment. In eight MM cell lines, high IRF4 levels correlated with increased lenalidomide sensitivity. The clinical significance of this observation was investigated in 154 patients with MM. Among MM patients with high levels of IRF4 expression, treatment with lenalidomide led to a significantly longer overall survival than other therapies in a retrospective analysis. These data confirm the central role of IRF4 in MM pathogenesis; indicate that this is an important mechanism by which lenalidomide exerts its antitumour effects; and may provide a mechanistic biomarker to predict response to lenalidomide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2011.08689.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 38

  1. 10.1182/blood-2007-10-117838 · DOI
  2. 10.1053/j.seminhematol.2005.10.001 · DOI · Paper page
  3. 10.1016/j.ccr.2007.07.004 · DOI · Paper page
  4. 10.3109/10428191003721342 · DOI
  5. 10.1182/blood-2002-01-0104 · DOI
  6. 10.1016/j.immuni.2008.10.011 · DOI · Paper page
  7. 10.1093/jncimonographs/lgn011 · DOI
  8. 10.1038/leu.2009.147 · DOI · Paper page
  9. Dimopoulos M.A., 2011, Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement, Leukemia, 3, 1
  10. 10.1038/sj.leu.2404284 · DOI · Paper page
  11. 10.1158/0008-5472.CAN-08-4898 · DOI · Paper page
  12. 10.1172/JCI24096 · DOI
  13. 10.1038/leu.2008.320 · DOI · Paper page
  14. 10.1517/14656560802627903 · DOI
  15. 10.1016/j.leukres.2006.01.010 · DOI
  16. 10.2174/156800910791054239 · DOI · Paper page
  17. 10.1084/jem.191.8.1281 · DOI · Paper page
  18. 10.1097/PAS.0b013e3181bb9a18 · DOI
  19. 10.1084/jem.190.12.1837 · DOI
  20. 10.1038/sj.leu.2404895 · DOI
  21. 10.1182/blood.V96.9.2943 · DOI · Paper page
  22. 10.1182/blood-2010-04-278432 · DOI · Paper page
  23. 10.1038/ng1097-226 · DOI · Paper page
  24. 10.1111/j.1349-7006.2002.tb01307.x · DOI
  25. Li S., 2009, Lenalidomide shuts down the translational machinery in multiple myeloma cells resulting in down‐regulation of critical transcription factors such as C/EBPβ and IRF4 [abstract], Blood, 114
  26. 10.3324/haematol.10682 · doi:10.3324/haematol.10682
  27. 10.1128/MCB.01946-07 · DOI
  28. 10.1084/jem.20011128 · DOI · Paper page
  29. 10.1053/j.seminhematol.2005.10.004 · DOI
  30. 10.1182/blood-2008-12-196238 · DOI · Paper page
  31. 10.1158/1078-0432.CCR-08-1845 · DOI · Paper page
  32. 10.1111/j.0303-6987.2005.00298.x · doi:10.1111/j.0303-6987.2005.00298.x
  33. 10.1038/sj.leu.2401696 · DOI · Paper page
  34. 10.1038/sj.leu.2403833 · DOI
  35. 10.1182/blood.V88.6.2219.bloodjournal8862219 · DOI
  36. 10.1080/10428190802005191 · DOI
  37. 10.1158/0008-5472.CAN-06-2317 · DOI · Paper page
  38. 10.1182/blood-2006-07-038703 · DOI · Paper page

Cited by

See all 181

Metadata

Authors
Lopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., Hilgarth, B., Zojer, N., Gisslinger, H., Ludwig, H., Daniel, T., Jäger, U., & Chopra, R.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2011-06-24
Volume
154
Issue
3
Pages
325-336
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1537559901
Cited by
181
References
7
FWCI
9.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response. https://app.cochat.ai/papers/10.1111/j.1365-2141.2011.08689.x
The paper
Lopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., Hilgarth, B., Zojer, N., Gisslinger, H., Ludwig, H., Daniel, T., Jäger, U., & Chopra, R. (2011). Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2011.08689.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.